Acquired hemophilia A: updated review of evidence and treatment guidance
R Kruse‐Jarres, CL Kempton, F Baudo… - American journal of …, 2017 - Wiley Online Library
Acquired hemophilia A (AHA) is a rare disease resulting from autoantibodies (inhibitors)
against endogenous factor VIII (FVIII) that leads to bleeding, which is often spontaneous and …
against endogenous factor VIII (FVIII) that leads to bleeding, which is often spontaneous and …
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation …
Abstract In 2013, the European Heart Rhythm Association (EHRA) published a Practical
Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation …
Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation …
Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report
Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …
[HTML][HTML] International recommendations on the diagnosis and treatment of acquired hemophilia A
Acquired hemophilia A (AHA), a rare bleeding disorder caused by neutralizing
autoantibodies against coagulation factor VIII (FVIII), occurs in both men and women without …
autoantibodies against coagulation factor VIII (FVIII), occurs in both men and women without …
Emicizumab for the treatment of acquired hemophilia A
Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting
autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents …
autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents …
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study
A Tiede, R Klamroth, RE Scharf… - Blood, The Journal …, 2015 - ashpublications.org
Acquired hemophilia A (AHA) is caused by autoantibodies against factor VIII (FVIII).
Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of …
Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of …
Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
R Kruse‐Jarres, J St‐Louis, A Greist, A Shapiro… - …, 2015 - Wiley Online Library
Acquired haemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against
human factor VIII (hFVIII). OBI‐1 is an investigational, B‐domain deleted, recombinant FVIII …
human factor VIII (hFVIII). OBI‐1 is an investigational, B‐domain deleted, recombinant FVIII …
[PDF][PDF] Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia:.
PW Collins, E Chalmers, DP Hart, R Liesner… - British journal of …, 2013 - cnhp.cz
1School of Medicine, Cardiff University, University Hospital of Wales, Wales, 2Royal
Hospital for Sick Children, Glasgow, 3The London School of Medicine and Dentistry, Royal …
Hospital for Sick Children, Glasgow, 3The London School of Medicine and Dentistry, Royal …
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study
Background Acquired haemophilia A is caused by neutralising autoantibodies against
coagulation factor VIII, leading to severe bleeding. Standard treatment involves …
coagulation factor VIII, leading to severe bleeding. Standard treatment involves …